Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Rocket Pharmaceuticals sold its Rare Pediatric Disease Priority Review Voucher for $180 million in non-dilutive capital. The transaction extends the company's cash runway into the second quarter of 2028, significantly de-risking its financial position.
Key figures
- Deal Value Usd
- 180000000
- Cash Runway
- second quarter of 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.